title: Serendipity in splendid isolation: rapamycin.
abstract: In this issue of Blood, Bride et al report results of the first prospective multi-institutional trial of a long-term single-agent therapy for refractory cytopenias using rapamycin in 30 patients and show remarkable efficacy in children with autoimmune lymphoproliferative syndrome (ALPS).
authors.affiliation: NATIONAL INSTITUTES OF HEALTH.
authors.forename: V Koneti
authors.identifier: http://orcid.org/0000-0002-7881-6902
authors.initials: VK
authors.lastname: Rao
mesh_terms: D001327:Autoimmune Diseases / Q000188:drug therapy*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006402:Hematologic Diseases / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D016879:Salvage Therapy; D020123:Sirolimus / Q000627:therapeutic use*
chemical_list: D007166:Immunosuppressive Agents; D020123:Sirolimus